Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
09/06/2022 - 07:55 AM
NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24th Annual Global Investment Conference, on September 13, 2022 in New York, NY .
Presentation Details:
H.C. Wainwright 24th Annual Global Investment Conference Date: Tuesday, September 13 , 2022 Time: 3:00 p.m. E.T. Location: Lotte New York Palace, New York, NY
The presentation will be viewable starting Tuesday, September 13, 2022 , at 3:00 p.m. Eastern time , and will be available for 90 days, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab .
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel , Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801 , which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901 ).
For more information, please visit www.oramed.com .
Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
Company contact: Zach Herschfus +1-844-9-ORAMEDzach@oramed.com
View original content:https://www.prnewswire.com/news-releases/oramed-to-present-at-hc-wainwright-24th-annual-global-investment-conference-301618100.html
SOURCE Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals, Inc
ORMP Rankings
#5216 Ranked by Stock Gains
ORMP Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
New York
About ORMP
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg